Blockade of the interleukin‐21/interleukin‐21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis

• Published in: Arthritis and rheumatism Vol. 56; no. 4; pp. 1152 - 1163
• Main Authors: Young, Deborah A., Hegen, Martin, Ma, Hak Ling Margery, Whitters, Matthew J., Albert, Leo M., Lowe, Leslie, Senices, Mayra, Wu, Paul W., Sibley, Barbara, Leathurby, Yelena, Brown, Tom P., Nickerson‐Nutter, Cheryl, Keith, James C., Collins, Mary
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.04.2007; Wiley
• Subjects: Animals; Arthritis, Experimental - metabolism; Arthritis, Experimental - pathology; Arthritis, Experimental - prevention & control; Biological and medical sciences; Cells, Cultured; Cytokines - blood; Cytokines - genetics; Diseases of the osteoarticular system; Dose-Response Relationship, Drug; Gene Expression; Immunoglobulin Fc Fragments - administration & dosage; Inflammatory joint diseases; Interleukin-21 Receptor alpha Subunit - administration & dosage; Interleukin-21 Receptor alpha Subunit - metabolism; Interleukins - antagonists & inhibitors; Interleukins - metabolism; Lymph Nodes - drug effects; Lymph Nodes - metabolism; Lymphocyte Activation; Male; Medical sciences; Mice; Mice, Inbred DBA; Miscellaneous. Osteoarticular involvement in other diseases; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Receptors, Interleukin-21 - antagonists & inhibitors; Receptors, Interleukin-21 - metabolism; Receptors, Tumor Necrosis Factor - administration & dosage; Receptors, Tumor Necrosis Factor - antagonists & inhibitors; Receptors, Tumor Necrosis Factor - genetics; Recombinant Fusion Proteins - administration & dosage; RNA, Messenger - metabolism; Spleen - drug effects; Spleen - metabolism; T-Lymphocytes - drug effects; T-Lymphocytes - metabolism; Spleen; Immunopathology; Animal model; Lymph node; Interleukin; Cytokine; Diseases of the osteoarticular system; Rheumatology; Autoimmune disease; Inflammatory joint disease; Arthritis; Joint; Chronic; Treatment; Rheumatoid arthritis; Interferon
• ISSN: 0004-3591; 1529-0131
• DOI: 10.1002/art.22452

Objective Interleukin‐21 (IL‐21) is a T cell–derived cytokine that modulates T cell, B cell, and natural killer cell responses. In this study, the effects of blocking IL‐21 were examined in 2 rodent models of rheumatoid arthritis (RA) to determine whether IL‐21 contributes to their pathologic processes. Methods DBA/1 mice were immunized with bovine type II collagen and then treated with murine IL‐21 receptor Fc fusion protein (IL‐21R.Fc), which was initiated after the onset of arthritis symptoms in 10% of the cohort. The mice were assessed 3 times per week for signs of disease, including histologic features as well as serum cytokine, Ig, and cytokine messenger RNA (mRNA) levels in the paws. In a separate experiment, Lewis rats were immunized with Freund's complete adjuvant followed by administration of IL‐21R.Fc at the peak of inflammation in the joints. Rats were assessed daily for histologic features and for scoring of arthritis severity. In addition, the effects of IL‐21R.Fc on the production of interferon‐γ (IFNγ) by T cells were examined. Results Treatment of DBA/1 mice with IL‐21R.Fc reduced the clinical and histologic signs of collagen‐induced arthritis. Nonspecific IgG1 levels were decreased in response to treatment. The levels of IL‐6 mRNA in the paws and the serum IL‐6 levels were decreased after treatment with IL‐21R.Fc. IFNγ mRNA levels were increased in the paws, and the addition of IL‐21R.Fc to collagen‐activated lymph node cultures enhanced the levels of IFNγ. Collagen‐specific spleen cell responses in IL‐21R.Fc–treated mice were observed as reduced levels of IFNγ and increased levels of IL‐6. Treatment of Lewis rats with IL‐21R.Fc after induction of adjuvant‐induced arthritis resulted in reversal of disease signs and improvements in histologic parameters. Conclusion These findings demonstrate a pathogenic role for IL‐21 in animal models of RA, and support consideration of IL‐21 as a therapeutic target in human RA.